Reciprocating-flowing on-a-chip enables ultra-fast immunobinding for multiplexed rapid ELISA detection of SARS-CoV-2 antibody.

The worldwide epidemic of novel coronavirus disease (COVID-19) has led to a strong demand for highly efficient immunobinding to achieve rapid and accurate on-site detection of SARS-CoV-2 antibodies. However, hour-scale time-consumption is usually required to ensure the adequacy of immunobinding on expensive large instruments in hospitals, and the common false negative or positive results often occur in rapid on-site immunoassay (e.g.

Overexpression of TBL1XR1 confers tumorigenic capability and promotes recurrence of osteosarcoma.

Osteosarcoma is the most common malignant bone tumor in childhood and adolescence; however, the mechanism of this malignancy remains uncertain. Transducin (beta)-like 1 × -linked receptor 1 (TBL1XR1) plays an important role in controlling the transcriptional switch between gene activation and gene repression. However, the clinical significance and the precise biological function of TBL1XR1 in osteosarcoma remain unclear.